What happens when a patient’s only treatment hope rests with a promising but not yet locally approved therapy? At Novartis, we are providing a lifeline of access to innovative medicines under review or not yet approved locally when no other treatment options are available.

State-of-the-art Novartis manufacturing facility in Indianapolis fortifies the foundation of an entirely new paradigm in pharmaceutical drug delivery.

John Tsai, Head of Global Drug Development and Chief Medical Officer, describes how he balances innovation and patient needs.